Nose-to-brain drug delivery for the treatment of Alzheimer’s disease: current advancements and challenges

References

• WHO. Dementia; 2021 [ cited 2021 Oct 12]. https://www.who.int/news-room/fact-sheets/detail/dementia#:~:text=Worldwide%2C%20around%2050%20million%20people,60%E2%80%9370%25%20of%20cases
   Google Scholar
• 2020 alzheimer’s disease facts and figures. 2020;16(3):391–460. https://alz-journals.onlinelibrary.wiley.com/doi/abs/10.1002/alz.12068.
   Google Scholar
• Agrawal M, Saraf S, Saraf S, et al. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release. 2018 Jul 10;281:139–177.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Saraf S, Saraf S, et al. Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region. Expert Opin Drug Deliv. 2018 Jun;15(6):589–617.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Prathyusha E, Ahmed H, et al. Biomaterials in treatment of alzheimer’s disease. Neurochem Int. 2021 May 01;145:105008. 2021.
   PubMed Web of Science ®Google Scholar
• Dubey SK, Lakshmi KK, Krishna KV, et al. Insulin mediated novel therapies for the treatment of alzheimer’s disease. Life Sci. 2020 May 15;249:117540.
   PubMed Web of Science ®Google Scholar
• Dubey SK, Ram MS, Krishna KV, et al. Recent expansions on cellular models to uncover the scientific barriers towards drug development for alzheimer’s disease. Cell Mol Neurobiol. 2019 Mar;39(2):181–209.
   PubMed Web of Science ®Google Scholar
• Alexander A, Agrawal M, Uddin A, et al. Recent expansions of novel strategies towards the drug targeting into the brain. Int J Nanomedicine. 2019;14:5895–5909.
   PubMed Web of Science ®Google Scholar
• USFDA. FDA grants accelerated approval for alzheimer’s drug. U.S. Food & Drug Administration; 2021 [ cited 2021 Dec 28]. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
   Google Scholar
• Alzforum. GV-971. In: Cure ANfA, ed. Therapeutics. USA 2021; [ cited 2021 Dec 29]. https://www.alzforum.org/therapeutics/gv-971
   Google Scholar
• Abolhasanzadeh Z, Ashrafi H, Badr P, et al. Traditional neurotherapeutics approach intended for direct nose to brain delivery. J Ethnopharmacol. 2017 Sep 14;209:116–123.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Saraf S, Saraf S, et al. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Control Release. 2020 May 10; 321:372–415. 2020.
   PubMed Web of Science ®Google Scholar
• Akel H, Ismail R, Csóka I. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in alzheimer’s disease. Eur J Pharm Biopharm. 2020 Mar;148:38–53.
   PubMed Web of Science ®Google Scholar
• Alexander A, Saraf S. Nose-to-brain drug delivery approach: a key to easily accessing the brain for the treatment of alzheimer’s disease. Neural Regen Res. 2018 Dec;13(12):2102–2104.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Saraf S, Saraf S, et al. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery. J Control Release. 2020 Nov 10; 327:235–265. 2020.
   PubMed Web of Science ®Google Scholar
• Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies. J Control Release. 2018 Jan 28;270:89–100.
   PubMed Web of Science ®Google Scholar
• Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008 Dec 10;9(Suppl 3):S5. Suppl 3.
   PubMedGoogle Scholar
• Mittal D, Ali A, Md S, et al. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 2014 Mar;21(2):75–86.
   PubMed Web of Science ®Google Scholar
• Battaglia L, Panciani PP, Muntoni E, et al. Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery. Expert Opin Drug Deliv. 2018 Apr;15(4):369–378.
   PubMed Web of Science ®Google Scholar
• Long Y, Yang Q, Xiang Y, et al. Nose to brain drug delivery - A promising strategy for active components from herbal medicine for treating cerebral ischemia reperfusion. Pharmacol Res. 2020 Sep 01; 159:104795. 2020.
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv. 2013 Jul;10(7):957–972.
   PubMed Web of Science ®Google Scholar
• Grassin-Delyle S, Buenestado A, Naline E, et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012 Jun;134(3):366–379.
   PubMed Web of Science ®Google Scholar
• St John JA, Walkden H, Nazareth L, et al. Burkholderia pseudomallei rapidly infects the brain stem and spinal cord via the trigeminal nerve after intranasal inoculation. Infect Immun. 2016 Sep;84(9):2681–2688.
   PubMed Web of Science ®Google Scholar
• Bourganis V, Kammona O, Alexopoulos A, et al. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm. 2018 Jul;128:337–362.
   PubMed Web of Science ®Google Scholar
• Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release. 2014 Sep 10;189:133–140.
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010 Apr;99(4):1654–1673.
   PubMed Web of Science ®Google Scholar
• Bustamante-Marin XM, Ostrowski LE. Cilia and mucociliary clearance. Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4). DOI:https://doi.org/10.1101/cshperspect.a028241.
   Google Scholar
• Movia D, Bruni-Favier S, Prina-Mello A. In vitro alternatives to acute inhalation toxicity studies in animal models-a perspective. Front Bioeng Biotechnol. 2020;8:549.
   PubMed Web of Science ®Google Scholar
• Bonferoni MC, Rossi S, Sandri G, et al. Nanoemulsions for “Nose-to-Brain” drug delivery. Pharmaceutics. 2019 Feb 17;11(2). DOI:https://doi.org/10.3390/pharmaceutics11020084.
   Google Scholar
• Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012 May 15;64(7):614–628.
   PubMed Web of Science ®Google Scholar
• Bourganis V, Kammona O, Alexopoulos A, et al. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm. 2018 Jul 01;128:337–362. 2018.
   PubMed Web of Science ®Google Scholar
• Keller L-A, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2021 Jan 25. 2021. DOI:https://doi.org/10.1007/s13346-020-00891-5.
   Google Scholar
• Casettari L, Illum L. Chitosan in nasal delivery systems for therapeutic drugs. J Control Release. 2014;190:189–200. 2014.
   PubMed Web of Science ®Google Scholar
• Wang Z, Xiong G, Tsang WC, et al. Nose-to-brain delivery. J Pharmacol Exp Ther. 2019;370(3):593.
   PubMed Web of Science ®Google Scholar
• Ruigrok MJ, de Lange EC. Emerging insights for translational pharmacokinetic and pharmacokinetic-pharmacodynamic studies: towards prediction of nose-to-brain transport in humans. AAPS J. 2015;17(3):493–505.
   PubMed Web of Science ®Google Scholar
• Selvaraj K, Gowthamarajan K, Karri V. Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting. Artif Cells Nanomed Biotechnol. 2018 Dec;46(8):2088–2095.
   PubMed Web of Science ®Google Scholar
• Rassu G, Soddu E, Posadino AM, et al. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for alzheimer’s therapy. Colloids Surf B Biointerfaces. 2017;152:296–301. 2017.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Lapierre J, Ojha CR, et al. Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation. Sci Rep. 2017;7(1):1–10. 2017.
   PubMedGoogle Scholar
• Meister S, Zlatev I, Stab J, et al. Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model. Alzheimers Res Ther. 2013;5(6):51. 2013.
   PubMed Web of Science ®Google Scholar
• Bhise SB, Yadav AV, Avachat AM, et al. Bioavailability of intranasal drug delivery system. Asian J Pharm (AJP). 2014;2(4).
   Google Scholar
• Hassane FS, Saleh AF, Abes R, et al. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci. 2010;67(5):715–726.
   PubMed Web of Science ®Google Scholar
• Kanazawa T. Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles. Med. Devices Evid Res. 2015. 2015;8: 57–64.
   Google Scholar
• Kim I-D, Sawicki E, Lee H-K, et al. Robust neuroprotective effects of intranasally delivered iNOS siRNA encapsulated in gelatin nanoparticles in the postischemic brain. Nanomedicine. 2016 Jul 01; 12(5):1219–1229. 2016.
   PubMed Web of Science ®Google Scholar
• Kanazawa T, Kaneko M, Niide T, et al. Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide. Int J Pharm. 2017;530(1):195–200.
   PubMedGoogle Scholar
• Agrawal M, Saraf S, and Saraf S, et al. Stimuli-responsive in situ gelling system for nose-to-brain drug delivery. J Control Release. 2020;327:235–265.
   PubMed Web of Science ®Google Scholar
• Calderon-Garcidueñas AL, Duyckaerts C. Alzheimer disease. Handb Clin Neurol. 2018;145:325–337.
   Google Scholar
• Citron M, Oltersdorf T, Haass C, et al. Mutation of the β-amyloid precursor protein in familial alzheimer’s disease increases β-protein production. Nature. 1992;360(6405):672–674.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhao Y, Yu M, et al. Reassembly of native components with donepezil to execute dual-missions in alzheimer’s disease therapy. J Control Release. 2019;296:14–28.
   PubMed Web of Science ®Google Scholar
• Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies. J Control Release. 2018;270:89–100.
   PubMed Web of Science ®Google Scholar
• IFF DS, Dos Santos TQ, Placido RV, et al. The liquid crystalline phase behaviour of a nasal formulation modifies the brain disposition of donepezil in rats in the treatment of alzheimer’s disease. Colloids Surf B Biointerfaces. 2021;203:111721.
   PubMed Web of Science ®Google Scholar
• Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and alzheimer’s disease: shared pathology and treatment? Br J Clin Pharmacol. 2011 Mar;71(3):365–376.
   PubMed Web of Science ®Google Scholar
• Kosaraju J, Gali CC, Khatwal RB, et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced alzheimer’s disease. Neuropharmacology. 2013 Sep;72:291–300.
   PubMed Web of Science ®Google Scholar
• Kosaraju J, Murthy V, Khatwal RB, et al. Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced alzheimer’s disease. J Pharm Pharmacol. 2013 Dec;65(12):1773–1784.
   PubMed Web of Science ®Google Scholar
• Isik AT, Soysal P, Yay A, et al. The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without alzheimer’s disease. Diabetes Res Clin Pract. 2017 Jan;123:192–198.
   PubMed Web of Science ®Google Scholar
• Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm. 2008 Nov;70(3):735–740.
   PubMed Web of Science ®Google Scholar
• Wilson B, Alobaid BNM, Geetha KM, et al. Chitosan nanoparticles to enhance nasal absorption and brain targeting of sitagliptin to treat alzheimer’s disease. J Drug Delivery Sci Technol. 2021;61:102176.
   Web of Science ®Google Scholar
• Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol. 2001 Jan 01;53(1):3–22. 2001.
   PubMed Web of Science ®Google Scholar
• Jiang L, Gao L, Wang X, et al. The application of mucoadhesive polymers in nasal drug delivery. Drug Dev Ind Pharm. 2010;36(3):323–336.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Furubayashi T, Tomisaki M, et al. Nasal drug absorption from powder formulations: the effect of three types of hydroxypropyl cellulose (HPC). Eur J Pharm Sci. 2017;96:284–289.
   PubMed Web of Science ®Google Scholar
• Alsarra IA, Hamed AY, Mahrous GM, et al. Mucoadhesive polymeric hydrogels for nasal delivery of acyclovir. Drug Dev Ind Pharm. 2009;35(3):352–362.
   PubMed Web of Science ®Google Scholar
• Brannigan RP, Khutoryanskiy VV. Progress and current trends in the synthesis of novel polymers with enhanced mucoadhesive properties. Macromol Biosci. 2019 Oct 01;19(10):1900194. 2019.
   Web of Science ®Google Scholar
• Abd El-Hameed M, Kellaway I. Preparation and in vitro characterisation of mucoadhesive polymeric microspheres as intra-nasal delivery systems. Eur J Pharm Biopharm. 1997;44(1):53–60.
   Web of Science ®Google Scholar
• Tas C, Ozkan CK, Savaser A, et al. Nasal absorption of metoclopramide from different Carbopol® 981 based formulations: in vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm. 2006;64(2):246–254.
   PubMed Web of Science ®Google Scholar
• Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57(11):1556–1568.
   PubMed Web of Science ®Google Scholar
• Leitner VM, Walker GF, Bernkop-Schnürch A. Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur J Pharm Biopharm. 2003;56(2):207–214.
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal drug delivery - recent developments and future prospects. J Control Release. 2012;161(2):254–263. 2012.
   PubMed Web of Science ®Google Scholar
• Balakrishnan P, Park E-K, Song C-K, et al. Carbopol-incorporated thermoreversible gel for intranasal drug delivery. Molecules. 2015;20(3):4124–4135.
   PubMed Web of Science ®Google Scholar
• Fakhari A, Corcoran M, Schwarz A. Thermogelling properties of purified poloxamer 407. Heliyon. 2017;3(8):e00390.
   PubMed Web of Science ®Google Scholar
• Katona G, Sipos B, Budai-Szűcs M, et al. Development of in situ gelling meloxicam-human serum albumin nanoparticle formulation for nose-to-brain application. Pharmaceutics. 2021;13(5):646.
   PubMed Web of Science ®Google Scholar
• Porfiryeva NN, Nasibullin SF, Abdullina SG, et al. Acrylated Eudragit® E PO as a novel polymeric excipient with enhanced mucoadhesive properties for application in nasal drug delivery. Int J Pharm. 2019;562:241–248.
   PubMedGoogle Scholar
• Blanco-Silvente L, Castells X, Saez M, et al. Discontinuation, efficacy, and safety of cholinesterase inhibitors for alzheimer’s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients. Int J Neuropsychopharmacol. 2017;20(7):519–528.
   PubMed Web of Science ®Google Scholar
• Loy C, Schneider L. Galantamine for alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;(1). DOI: https://doi.org/10.1002/14651858.CD001747.pub3.
   Google Scholar
• Tirucherai GS, Yang C, Mitra AK. Prodrugs in nasal drug delivery. Expert Opin Biol Ther. 2001;1(1):49–66.
   PubMed Web of Science ®Google Scholar
• Bakker C, van der Aart J, Hart EP, et al. Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine. Alzheimer's Dementia. 2020;6(1):e12093.
   Google Scholar
• Dahlin M, Björk E. Nasal administration of a physostigmine analogue (NXX-066) for alzheimer’s disease to rats. Int J Pharm. 2001;212(2):267–274.
   PubMedGoogle Scholar
• Jung BH, Chung BC, Chung S-J, et al. Prolonged delivery of nicotine in rats via nasal administration of proliposomes. J Control Release. 2000;66(1):73–79.
   PubMed Web of Science ®Google Scholar
• Warnken ZN, Smyth HD, Watts AB, et al. Formulation and device design to increase nose to brain drug delivery. J Drug Delivery Sci Technol. 2016;35:213–222.
   Web of Science ®Google Scholar
• Scherließ R. Nasal formulations for drug administration and characterization of nasal preparations in drug delivery. Ther Deliv. 2020;11(3):183–191.
   PubMed Web of Science ®Google Scholar
• Rao NV, Ko H, Lee J, et al. Recent progress and advances in stimuli-responsive polymers for cancer therapy. Front Bioeng Biotechnol. 2018;6:110.
   PubMed Web of Science ®Google Scholar
• Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer's disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012 Jan;69(1):29–38.
   PubMed Web of Science ®Google Scholar
• Djupesland PG. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008 Sep 9;71(11):864.
   PubMed Web of Science ®Google Scholar
• Sélam JL. Inhaled insulin: promises and concerns. J Diabetes Sci Technol. 2008 Mar;2(2):311–315.
   PubMedGoogle Scholar
• Rapoport A, Winner P. Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache. 2006 Nov;46(Suppl s4):S192–201.
   PubMedGoogle Scholar
• Erdő F, Bors LA, Farkas D, et al. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018 Oct; 143: 155–170.
   PubMed Web of Science ®Google Scholar
• Chatterjee B, Gorain B, Mohananaidu K, et al. Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges. Int J Pharm. 2019 Jun 30;565:258–268.
   PubMed Web of Science ®Google Scholar
• Chatterjee B, Gorain B, Mohananaidu K, et al. Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges. Int J Pharm. 2019;565:258–268. 2019.
   PubMed Web of Science ®Google Scholar
• Vitorino C, Silva S, Bicker J, et al. Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges. Drug Discov Today. 2019;24(9):1911–1923.
   PubMed Web of Science ®Google Scholar
• Hong -S-S, Oh KT, Choi H-G, et al. Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives. Pharmaceutics. 2019;11(10):540.
   PubMed Web of Science ®Google Scholar
• Keller L-A, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2021;1–23.
   Web of Science ®Google Scholar
• Gangane PS, Ghormare NV, Mahapatra DK, et al. Gellan gum assisted fabrication and characterization of Donepezil Hydrochloride Mucoadhesive intranasal microspheres. Int J Curr Res Rev. 2020;12(19):105–115.
   Google Scholar
• Yalcin A, Soddu E, Turunc Bayrakdar E, et al. Neuroprotective effects of engineered polymeric nasal microspheres containing Hydroxypropyl-beta-cyclodextrin on beta-Amyloid (1-42)-induced toxicity. J Pharm Sci. 2016 Aug;105(8):2372–2380.
   PubMed Web of Science ®Google Scholar
• Gao Y, Almalki WH, Afzal O, et al. Systematic development of lectin conjugated microspheres for nose-to-brain delivery of rivastigmine for the treatment of alzheimer’s disease. Biomed Pharmacother. 2021 Sep;141:111829.
   PubMed Web of Science ®Google Scholar
• Sheng Y, Hu J, Shi J, et al. Stimuli-responsive carriers for controlled intracellular drug release. Curr Med Chem. 2019;26(13):2377–2388.
   PubMed Web of Science ®Google Scholar
• Wenyuan Chen RL, Zhu S, Jinqiu M, et al. Nasal timosaponin BII dually sensitive in situ hydrogels for the prevention of alzheimer’s disease induced by lipopolysaccharides. Int J Pharm. 2020;578:119115.
   PubMedGoogle Scholar
• Abouhussein DMN, Khattab A, Bayoumi NA, et al. Brain targeted rivastigmine mucoadhesive thermosensitive in situ gel: optimization, in vitro evaluation, radiolabeling, in vivo pharmacokinetics and biodistribution. J Drug Delivery Sci Technol. 2018;43:129–140.
   Web of Science ®Google Scholar
• Qian S, Wong YC, Zuo Z. Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. Int J Pharm. 2014 Jul 1;468(1–2):272–282.
   PubMed Web of Science ®Google Scholar
• Salatin S, Barar J, Barzegar-Jalali M, et al. Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: development, characterization, ex vivo permeation and cellular studies. Colloids Surf B Biointerfaces. 2017 Nov 1;159:629–638.
   PubMed Web of Science ®Google Scholar
• Patil RP, Pawara DD, Gudewar CS, et al. Nanostructured cubosomes in an in situ nasal gel system: an alternative approach for the controlled delivery of donepezil HCl to brain. J Liposome Res. 2019 Sep;29(3):264–273.
   PubMed Web of Science ®Google Scholar
• Strambeanu N, Demetrovici L, Dragos D. Natural Sources of Nanoparticles. In: Lungu M, Neculae A, Bunoiu M, et al., editors. Nanoparticles’ Promises and Risks: characterization, Manipulation, and Potential Hazards to Humanity and the Environment. Cham: Springer International Publishing; 2015. p. 9–19.
   Google Scholar
• Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta Gen Subj. 2013 Jun 01;1830(6):3670–3695. 2013.
   PubMed Web of Science ®Google Scholar
• Guerrini L, Alvarez-Puebla RA, Pazos-Perez N. Surface modifications of nanoparticles for stability in biological fluids. Materials (Basel). 2018 Jul 6;11(7). DOI:https://doi.org/10.3390/ma11071154.
   Google Scholar
• Charoo NA, Rahman Z, and Khan MA. Chapter 11 - Nanoparticles for improvement in oral bioavailability. In: Grumezescu AM, editor. Nanoarchitectonics in Biomedicine. The Netherlands: William Andrew Publishing; 2019. p. 371–410.
   Google Scholar
• Lv S, Wu Y, Cai K, et al. High drug loading and sub-quantitative loading efficiency of polymeric micelles driven by donor–receptor coordination interactions. J Am Chem Soc. 2018 Jan 31; 140(4):1235–1238. 2018.
   PubMed Web of Science ®Google Scholar
• Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019 Nov 21; 23(1):20. 2019.
   PubMedGoogle Scholar
• Luo Y, Yang H, Zhou Y-F HB. Dual and multi-targeted nanoparticles for site-specific brain drug delivery. J Control Release. 2020 Jan 10;317:195–215. 2020.
   PubMed Web of Science ®Google Scholar
• Begines B, Ortiz T, Pérez-Aranda M, et al. Polymeric nanoparticles for drug delivery: recent developments and future prospects. Nanomaterials (Basel). 2020;10(7):1403.
   PubMedGoogle Scholar
• Essa D, Kondiah PPD, Choonara YE, et al. The design of Poly(lactide-co-glycolide) nanocarriers for medical applications. Front Bioeng Biotechnol. 2020;8:48.
   PubMed Web of Science ®Google Scholar
• Kobylinska L, Patereha I, Finiuk N, et al. Comb-like PEG-containing polymeric composition as low toxic drug nanocarrier. Cancer Nanotechnol. 2018 Dec 20; 9(1):11. 2018.
   PubMed Web of Science ®Google Scholar
• Yanat M, Schroën K. Preparation methods and applications of chitosan nanoparticles; with an outlook toward reinforcement of biodegradable packaging. React Funct Polym. 2021 Apr 01;161:104849. 2021.
   Web of Science ®Google Scholar
• Łukasiewicz S, Mikołajczyk A, Błasiak E, et al. Polycaprolactone nanoparticles as promising candidates for nanocarriers in novel nanomedicines. Pharmaceutics. 2021;13(2):191.
   PubMed Web of Science ®Google Scholar
• Kong M, Peng X, Cui H, et al. pH-responsive polymeric nanoparticles with tunable sizes for targeted drug delivery. RSC Adv. 2020;10(9):4860–4868.
   PubMed Web of Science ®Google Scholar
• de Oliveira Junior ER, Santos LCR, Salomao MA, et al. Nose-to-brain drug delivery mediated by polymeric nanoparticles: influence of PEG surface coating. Drug Deliv Transl Res. 2020 Dec;10(6):1688–1699.
   PubMed Web of Science ®Google Scholar
• Hanafy AS, Farid RM, Helmy MW, et al. Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in alzheimer’s disease management. Drug Deliv. 2016 Oct;23(8):3111–3122.
   PubMed Web of Science ®Google Scholar
• Meng Q, Wang A, Hua H, et al. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of alzheimer’s disease. Int J Nanomedicine. 2018;13:705–718.
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci. 2018;13(4):288–303.
   PubMed Web of Science ®Google Scholar
• Alexander A, Agrawal M, Saraf S, et al. Formulation strategies of nano lipid carrier for effective brain targeting of Anti-AD drugs. Current Pharmaceutical Design. 2020;26(27):80–3269.
   Web of Science ®Google Scholar
• Dhaliwal HK, Fan Y, Kim J, et al. Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes. Mol Pharm. 2020;17(6):1996–2005.
   PubMedGoogle Scholar
• Zhang H. Thin-film hydration followed by extrusion method for liposome preparation. Methods Mol Biol. 2017;1522:17–22.
   PubMedGoogle Scholar
• Maja L, Željko K, Mateja P. Sustainable technologies for liposome preparation. J Supercrit Fluids. 2020 Nov 01;165:104984. 2020.
   Web of Science ®Google Scholar
• Jaafar-Maalej C, Diab R, Andrieu V, et al. Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation. J Liposome Res. 2010 Sep;20(3):228–243.
   PubMed Web of Science ®Google Scholar
• Reza JNM, Tafaghodi M, S.A.A.Gh ST. Evaluation of the clearance characteristics of liposomes in the human nose by gamma-scintigraphy. Iranian Journal of Pharmaceutical Research. 2005;4:3–11.
   Google Scholar
• Corace G, Angeloni C, Malaguti M, et al. Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. J Liposome Res. 2014 Dec;24(4):323–335.
   PubMed Web of Science ®Google Scholar
• Zheng X, Shao X, Zhang C, et al. Intranasal H102 peptide-loaded liposomes for brain delivery to treat alzheimer’s disease. Pharm Res. 2015 Dec;32(12):3837–3849.
   PubMed Web of Science ®Google Scholar
• Anand A, Arya M, Kaithwas G, et al. Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. elegans model. Journal of Drug Delivery Science and Technology. 2019;49:219–226.
   Web of Science ®Google Scholar
• Rajput AP, Butani SB. Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: formulation, optimization and in vivo characterization. J Drug Delivery Sci Technol. 2019;51:214–223.
   Web of Science ®Google Scholar
• Kulkarni JA, Chen S, Tam YYC. Scalable production of lipid nanoparticles containing Amphotericin B. Langmuir. 2021 Jun 22;37(24):7312–7319.
   PubMed Web of Science ®Google Scholar
• WA B, MJ D, Ml N. Brain uptake of the glucagon-like peptide-1 antagonist exendin (9-39) after intranasal administration. J Pharmacol Exp Ther. 2004;309(2):469–475.
   PubMed Web of Science ®Google Scholar
• Falcone JA, Salameh TS, Yi X, et al. Intranasal administration as a route for drug delivery to the brain: evidence for a unique pathway for albumin. J Pharmacol Exp Ther. 2014;351(1):54–60. 2014.
   PubMed Web of Science ®Google Scholar
• Nonaka N, Farr SA, Nakamachi T, et al. Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins. Peptides. 2012;36(2):168–175. 2012.
   PubMed Web of Science ®Google Scholar
• Meredith ME, Salameh TS, Banks WA. Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases. AAPS J. 2015;17(4):780–787.
   PubMed Web of Science ®Google Scholar
• Huang Y-Y, Fang N, Luo H-R, et al. RP1, a RAGE antagonist peptide, can improve memory impairment and reduce Aβ plaque load in the APP/PS1 mouse model of alzheimer’s disease. Neuropharmacology. 2020;180:108304.
   PubMed Web of Science ®Google Scholar
• Cristiano C, Volpicelli F, Lippiello P, et al. Neutralization of IL‐17 rescues amyloid‐β‐induced neuroinflammation and memory impairment. Br J Pharmacol. 2019;176(18):3544–3557.
   PubMed Web of Science ®Google Scholar
• Miya Shaik M, Tamargo I, Abubakar M, et al. The role of microRNAs in alzheimer’s disease and their therapeutic potentials. Genes (Basel). 2018;9(4):174. 2018.
   Web of Science ®Google Scholar
• Rusca N, and Monticelli S. MiR-146a in immunity and disease. Mol Biol Int. 2011;25(8):2011.
   Google Scholar
• Ayers D, Scerri C. Non-coding RNA influences in dementia. Noncoding RNA Res. 2018;3(4):188–194.
   PubMedGoogle Scholar
• Mai H, Fan W, Wang Y, et al. Intranasal administration of miR-146a agomir rescued the pathological process and cognitive impairment in an AD mouse model. Mol Ther Nucleic Acids. 2019;18:681–695.
   PubMedGoogle Scholar
• John Hoekman SR, Aurora SK, Shrewsbury SB. The upper nasal space—a novel delivery route ideal for central nervous system drugs. US Neurol. 2020;16(1):25–31.
   Google Scholar
• Islam SU, Shehzad A, Ahmed MB, et al. Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders. Molecules. 2020 Apr 21;25(8). DOI:https://doi.org/10.3390/molecules25081929.
   Google Scholar
• Costa CP, Moreira JN, Sousa Lobo JM, et al. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies. Acta Pharm Sin B. 2021 Apr 01;11(4):925–940. 2021.
   PubMed Web of Science ®Google Scholar
• Quitterer U, AbdAlla S. Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system. Pharmacol Res. 2020 Apr 01;154:104230. 2020.
   PubMed Web of Science ®Google Scholar
• Kulkarni P, Rawtani D, Barot T. Design, development and in-vitro/in-vivo evaluation of intranasally delivered Rivastigmine and N-Acetyl Cysteine loaded bifunctional niosomes for applications in combinative treatment of alzheimer’s disease. Eur J Pharm Biopharm. 2021 Jun 01;163:1–15. 2021.
   PubMed Web of Science ®Google Scholar